claim: clinical evidence does also support corticosteroid treatment for 2019-ncov lung injury
evidence_1: no clinical data exist to indicate that net benefit is derived from corticosteroids in the treatment of respiratory infection due to rsv, influenza, sars-cov, or mers-cov.", "we conclude that corticosteroid treatment should not be used for the treatment of 2019-ncov-induced lung injury or shock outside of a clinical trial.", "corticosteroids have been investigated for respiratory syncytial virus (rsv) in clinical trials in children, with no conclusive evidence of benefit and are therefore not recommended."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )